the immunological mechanisms involved in eliminating pathogens and cancer cells, and to then try to control those mechanisms. He has already hired postdocs and technicians, and has ordered a two-photon microscope, an electron microscope, mass-spectrometry equipment and DNA-sequencing machines.
Not so bold
Despite the air of excitement that the awards have generated, some scientists point out that the FIRST grants were supposed to be bigger, and the projects bolder. In June 2009, the Council for Science and Technology Policy under the then-ruling Liberal Democratic Party announced that FIRST would distribute ¥270 billion. Council members had already selected the 30 recipients before the Democratic Party of Japan came to power.
The new government promised to re-evaluate all large spending programmes (see Nature 461, 854-855; 2009) , eventually slashing the budget and capping the largest projects at ¥5 billion. Some scientists had hoped to get considerably more: Yamanaka, for example, originally applied for ¥15 billion.
All of the grantees then had to reapply for their funding with scaled-back projects. "Every strategic research plan was shrunk and every brave enterprise was cut, " says Tokura. Yamanaka, for example, has dropped plans to carry out preclinical trials with induced pluripotent stem cells for diabetes and other diseases. Tonomura, meanwhile, says that his FIRST grant will still leave him ¥2 billion short of what his project requires, an amount he hopes to persuade Hitachi to chip in.
But with the money he already has in hand, he has no immediate plans to retire: "I want to create a history-making instrument, " he says. ■
David Cyranoski
See Editorial, page 957. Gathering the paperwork needed for the NIH application has been slowed by translation requirements (the original documents are in Hebrew) and other problems. One donating couple had not been informed that the lines could be used commercially and that they would not benefit financially -requirements that are spelled out in the NIH guidelines. ItskovitzEldor e-mailed patient re-consent forms, and institutional review board approvals for them, to WiCell on 8 April. "At this point, we have completed our part. But I am sure that more documents will be needed. The whole process may take some weeks or maybe more, " he says.
GETTING COMPETITIVE
The hoped-for approval can't come soon enough for Baker, who almost exclusively uses H9 in her lab. "The one that's really easy to produce in the lab, which grows well, is H9. That's why all the publications use it," she says. In early March, Baker submitted an NIH grant application to use H9 to examine how ES cells use cell signalling to form endoderm, which gives rise to many internal tissues. If H9 is not approved soon, she plans to write to reviewers and suggest that she switch to using H1. But that would require extra work to extrapolate data she has already generated in "extremely expensive" H9 experiments to H1. 
